BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
0.3591
-0.0038 (-1.05%)
At close: Jul 31, 2025, 4:00 PM
0.3699
+0.0108 (3.01%)
After-hours: Jul 31, 2025, 7:54 PM EDT
Exscientia Revenue
BioAtla had revenue of $11.00M in the twelve months ending March 31, 2025. In the year 2024, BioAtla had annual revenue of $11.00M.
Revenue (ttm)
$11.00M
Revenue Growth
n/a
P/S Ratio
1.69
Revenue / Employee
$180,328
Employees
61
Market Cap
20.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 250.00K | -179.00K | -41.72% |
| Dec 31, 2020 | 429.00K | -4.77M | -91.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 57.37B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
BCAB News
- 14 days ago - BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting - GlobeNewsWire
- 4 weeks ago - BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress - GlobeNewsWire
- 2 months ago - BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen - GlobeNewsWire
- 3 months ago - BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 3 months ago - BioAtla to Participate in the Citizens Life Sciences Conference - GlobeNewsWire
- 3 months ago - BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025 - GlobeNewsWire
- 3 months ago - BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire